gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Abhydrolase domain containing 12

Top mentioned proteins: ABHD6, fatty acid amide hydrolase, HAD, ACID, DSE
Papers on ABHD12
Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists.
Nevalainen et al., Kuopio, Finland. In Eur J Med Chem, Feb 2016
The designed compounds were not active when tested against various endocannabinoid targets (CB1R, CB2R, FAAH, MGL, ABHD6 and ABHD12), indicating compounds' selectivity for the GPR55.
Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors.
Nevalainen et al., Kuopio, Finland. In Bioorg Med Chem, Nov 2015
This compound at 10 μM concentration did not inhibit any other endocannabinoid hydrolases, such as FAAH, MAGL and ABHD12, or bind to the cannabinoid receptors (CB₁ and CB₂).
Novel ABHD12 mutations in PHARC patients: the differential diagnosis of deaf-blindness.
Usami et al., Matsumoto, Japan. In Ann Otol Rhinol Laryngol, May 2015
OBJECTIVE: This study examines ABHD12 mutation analysis in 2 PHARC patients, originally thought to be Usher syndrome.
Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay.
Cravatt et al., Los Angeles, United States. In Nat Chem Biol, Feb 2015
Recently, we determined that ABHD12 is a major brain lyso-PS lipase, implicating lyso-PSs in the neurological disease polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract (PHARC), which is caused by null mutations in the ABHD12 gene.
Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids.
Wevers et al., Nijmegen, Netherlands. In J Inherit Metab Dis, 2015
Boucher-Neuhäuser/Gordon Holmes syndrome (PNPLA6), PHARC syndrome (ABHD12), hereditary spastic paraplegia type 28, 54 and 56 (HSP28, DDHD1; HSP54, DDHD2; HSP56, CYP2U1), Lenz Majewski syndrome (PTDSS1), spondylometaphyseal dysplasia with cone-rod dystrophy (PCYT1A), atypical haemolytic-uremic syndrome due to DGKE deficiency (DGKE).
Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL).
Laitinen et al., Kuopio, Finland. In Mol Pharmacol, 2014
The primary route of inactivation of the endocannabinoid 2-arachidonoylglycerol in the central nervous system is through enzymatic hydrolysis, mainly carried out by monoacylglycerol lipase (MAGL), along with a small contribution by the α/β-hydrolase domain (ABHD) proteins ABHD6 and ABHD12.
Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: from syndromic to nonsyndromic retinal degeneration.
Ayuso et al., Lausanne, Switzerland. In Ophthalmology, 2014
A mutational screening was performed in 378 additional unrelated families for the exon-intron boundaries of the ABHD12 gene.
Discovery of triterpenoids as reversible inhibitors of α/β-hydrolase domain containing 12 (ABHD12).
Laitinen et al., Kuopio, Finland. In Plos One, 2013
Dysfunctional ABHD12 has been linked to the rare neurodegenerative disorder called PHARC (polyneuropathy, hearing loss, ataxia, retinosis pigmentosa, cataract).
Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects.
Bird et al., Seattle, United States. In Hum Mutat, 2013
PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataracts) is a recently described autosomal-recessive neurodegenerative disease caused by mutations in the α-β-hydrolase domain-containing 12 gene (ABHD12).
Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme.
Ross et al., United States. In Biochemistry, 2013
However, MAGL and other endocannabinoid hydrolases, FAAH, ABHD6, and ABHD12, did not have a role because of limited expression or no expression.
ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC.
Cravatt et al., Los Angeles, United States. In Proc Natl Acad Sci U S A, 2013
ABHD12(-/-) mice display massive increases in a rare set of very long chain LPS lipids that have been previously reported as Toll-like receptor 2 activators.
Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).
Laitinen et al., Kuopio, Finland. In J Lipid Res, 2012
The postgenomic proteins α/β-hydrolase domain containing (ABHD)6 and ABHD12 remain poorly characterized.
Optimization and characterization of triazole urea inhibitors for abhydrolase domain containing protein 6 (ABHD6)
Rosen et al., Bethesda, United States. In Unknown Journal, 2012
Three of the key enzymes responsible for 2-AG hydrolysis (and thus inactivation) are monoacylglycerol lipase (MAGL), abhydrolase domain containing proteins 6 (ABHD6), and ABHD12.
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.
Laitinen et al., Kuopio, Finland. In Acta Physiol (oxf), 2012
We review recent research on monoacylglycerol lipase (MAGL), ABHD6 and ABHD12, three serine hydrolases that together account for approx.
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma.
Kooner et al., London, United Kingdom. In Nat Genet, 2011
We identified 69 candidate genes, including genes involved in biliary transport (ATP8B1 and ABCB11), glucose, carbohydrate and lipid metabolism (FADS1, FADS2, GCKR, JMJD1C, HNF1A, MLXIPL, PNPLA3, PPP1R3B, SLC2A2 and TRIB1), glycoprotein biosynthesis and cell surface glycobiology (ABO, ASGR1, FUT2, GPLD1 and ST3GAL4), inflammation and immunity (CD276, CDH6, GCKR, HNF1A, HPR, ITGA1, RORA and STAT4) and glutathione metabolism (GSTT1, GSTT2 and GGT), as well as several genes of uncertain or unknown function (including ABHD12, EFHD1, EFNA1, EPHA2, MICAL3 and ZNF827).
Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.
Knappskog et al., Bergen, Norway. In Am J Hum Genet, 2010
Mutations in the ABHD12 gene cause polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract disease.
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.
Cravatt et al., Los Angeles, United States. In Chem Biol, 2007
Data reveal that 85% of brain 2-arachidonoylglycerol hydrolase activity can be ascribed to monoacylglycerol lipase(MAGL), and the remaining 15% is catalyzed by ABHD6 and ABHD12.
share on facebooktweetadd +1mail to friends